BioCryst (NASDAQ:BCRX) announced today that it is canceling its merger with Presidio Pharmaceuticals, an event that Motley Fool health care analyst Brenton Flynn predicted could happen last month. With BioCryst's Hep-C candidate impaired, and companies like Abbott (NYSE:ABT) and Gilead (NYSE:GILD) already light-years ahead in the race for an all-oral Hepatitis C regimen, it's easy to understand why a deal for Presidio and its phase-2-ready drug didn't make sense.
Motley Fool Returns
Discounted offers are only available to new members. Stock Advisor will renew at the then current list price. Stock Advisor list price is $199 per year.
Stock Advisor launched in February of 2002. Returns as of 10/18/2021.
Average returns of all recommendations since inception. Cost basis and return based on previous market day close.